SCHEMBL29366011

SCHEMBL29366011

O=C(N/N=C\c1c(O)ccc2ccccc12)c1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RRM1 P23921 5/20 1.00
IDO1 P14902 2/20 0.74
MEN1 O00255 7/20 0.70
KMT2A Q03164 7/20 0.70
NPC1 O15118 6/20 0.70
RAB9A P51151 6/20 0.69
PPARG P37231 1/20 0.68
PAX8 Q06710 1/20 0.67
KLF5 Q13887 3/20 0.63
POLB P06746 2/20 0.63
TDP1 Q9NUW8 1/20 0.63
MITF O75030 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
KDM4E B2RXH2 1/20 0.61
GLA P06280 1/20 0.61
MAPT P10636 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637575 1.00 RRM1 (1.00) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL4454258 1.00 RRM1 (1.00) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL1637574 1.00 RRM1 (1.00) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL18963239 0.88 RRM1 (1.00) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL1639477 0.87 RRM1 (0.77) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL1639479 0.87 RRM1 (0.77) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL12766750 0.87 RRM1 (0.77) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL683715 0.85 MEN1 (0.85) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL2847708 0.85 MEN1 (0.85) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL7602938 0.84 RRM1 (0.72) RRM1IDO1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4637832-A1 CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG Tubulis GmbH (DE) 2025-10-29 EP claimed
US-20240269313-A1 CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG TUBULIS GMBH (DE) 2024-08-15 US claimed
WO-2024133845-A1 CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG TUBULIS GMBH (DE) 2024-06-27 WO claimed
CN-116863729-A Multi-agent road traffic signal control method based on deep reinforcement learning algorithm 大连交通大学 2023-10-10 CN claimed
EP-4637832-A1 CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG Tubulis GmbH (DE) 2025-10-29 EP disclosed
US-20250250336-A1 NOVEL LILRB4 ANTIBODIES AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-08-07 US disclosed
CN-120053428-A Application of Zanthoxylum bungeanum toxin in preparing medicine for treating non-alcoholic fatty liver disease 济宁医学院 2025-05-30 CN disclosed
CN-119529092-A Anti-ACVR 2A antibodies and uses thereof 来凯医药科技(上海)有限公司 2025-02-28 CN disclosed
CN-119350394-A Phthalazinone compound, preparation method thereof, pharmaceutical composition and application 中国药科大学 2025-01-24 CN disclosed
US-12202895-B2 LILRB4 antibodies and uses thereof THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-01-21 US disclosed
US-20250002490-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD (CN) 2025-01-02 US disclosed
CN-118955358-A FXR partial agonist containing piperidine structure, and preparation method and application thereof 桂林医学院 2024-11-15 CN disclosed
CN-117285504-A Amino phenylacetamide derivative and preparation method and application thereof 桂林医学院 2023-12-26 CN disclosed
US-20230348457-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD (CN) 2023-11-02 US disclosed
CN-116863729-A Multi-agent road traffic signal control method based on deep reinforcement learning algorithm 大连交通大学 2023-10-10 CN disclosed
US-20230295151-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) 2023-09-21 US disclosed
US-11685735-B2 Pharmaceutical composition comprising berberine salts for the treatment of various diseases or disorders SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) 2023-06-27 US disclosed
WO-2023030503-A1 ANTI-ACVR2A ANTIBODIES AND USES THEREOF LAEKNA THERAPEUTICS SHANGHAI CO., LTD. (CN) 2023-03-09 WO disclosed
US-11422128-B2 Immunoassay employing sulfated polysaccharide LSI MEDIENCE CORPORATION (JP) 2022-08-23 US disclosed
CN-113987969-A Land-water dynamic simulation model of multi-elevation scale water flow network 严大莲 2022-01-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348457-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF CYP27A1, NR1H4, CYP7A1 RRM1 2076/4885IDO1 1440/4885MEN1 2170/4885
US-20250002490-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF CYP27A1, NR1H4, CYP7A1 RRM1 2076/4885IDO1 1440/4885MEN1 2170/4885
US-11685735-B2 Pharmaceutical composition comprising berberine salts for the treatment of various diseases or disorders CPT1B, CYP27A1, GLS2 RRM1 2324/4885IDO1 1005/4885MEN1 1912/4885
US-20230295151-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF CYP27A1, NR1H4, CYP7A1 RRM1 2076/4885IDO1 1440/4885MEN1 2170/4885
US-20240269313-A1 CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG PTH1R, SELPLG, CALCR RRM1 663/4885IDO1 4840/4885MEN1 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.